Roche Holding AG Stock Performance
Roche Holding AG trades at $57.25 per share with a market capitalization of approximately $318.7 billion, per SID market data. The stock exhibits notably low volatility with a beta of 0.166, indicating minimal correlation with broader market movements and reinforcing Roche's characterization as a defensive healthcare holding. Average daily trading volume stands at approximately 1.86 million shares, according to Massive/Polygon data. This low beta positions Roche significantly below the market average of 1.0, suggesting the stock has historically moved at roughly one-sixth the magnitude of the broader index. As a major pharmaceutical and diagnostics company within the healthcare sector, Roche's trading profile reflects the stability typically associated with large-cap pharma names. The combination of substantial market capitalization and subdued volatility metrics underscores the company's standing as a blue-chip defensive equity in global portfolios.
Roche Holding AG Valuation Analysis
Roche Holding AG currently carries a price-to-earnings ratio of 44.08, which positions it at a significant premium relative to many large-cap pharmaceutical peers, per SID market data. The company's PEG ratio stands at negative 1.44, reflecting a combination of elevated valuation and declining or negative projected earnings growth rates. The price-to-book ratio registers at 8.80, according to SEC filings, indicating the market values Roche at nearly nine times its book value, consistent with the intangible asset intensity typical of pharmaceutical companies with robust drug pipelines. Roche offers a dividend yield of approximately 3.09%, providing meaningful income return for shareholders in the healthcare sector. The elevated P/E multiple paired with a negative PEG ratio suggests the market is pricing in a recovery trajectory or pipeline catalysts, while the dividend yield partially offsets the premium valuation for income-oriented investors seeking healthcare exposure.
Smart Money Activity for RHHBY
Roche Holding AG registers a composite smart money score of 46 out of 100 with a neutral signal, according to SID market data. The breakdown reveals modest conviction across all tracked categories. Insider activity scores 12.5 out of 25, suggesting limited notable buying or selling from corporate officers and directors per SEC Form 4 filings. Institutional positioning scores 13.0 out of 25, indicating moderate but not aggressive accumulation among major fund managers tracked through 13F institutional filings. Dark pool activity registers at 8.5 out of 25, representing the weakest component and pointing to below-average institutional block trading interest. Congressional trading activity scores 12 out of 25, reflecting neither significant buying nor selling among tracked congressional members. The overall neutral reading across all four smart money dimensions indicates an absence of strong directional conviction from sophisticated market participants, with no single category exhibiting a compelling bullish or bearish tilt for RHHBY shares.
Roche Holding AG Earnings Outlook
Roche Holding AG has delivered earnings beats in three of its last four reported quarters, according to company earnings reports. The most recent quarter ending June 2025 showed actual earnings of 11.10 versus analyst estimates of 10.94, representing a positive surprise of 0.16. The June 2024 quarter produced the most substantial beat, with actual earnings of 10.23 compared to estimates of 9.34, a positive surprise of 0.89. The December 2024 quarter recorded actual earnings of 8.57 against estimates of 8.48, a modest beat of 0.09. The sole miss occurred in December 2023, when actual earnings of 8.47 narrowly fell short of the 8.49 estimate by 0.02. A clear seasonal pattern emerges in the data, with mid-year quarters consistently generating stronger absolute earnings than year-end quarters. The consecutive beat streak through 2024 and into 2025 demonstrates steady operational execution against analyst expectations.
Wall Street Analyst Ratings for RHHBY
Wall Street analyst coverage of Roche Holding AG reflects a divided outlook based on recent ratings activity. Per SID consensus data, the most recent actions from July 2026 include TD Cowen reiterating a Hold rating and Berenberg maintaining its Hold position, while Rothschild & Co Redburn reiterated a Buy recommendation. Jefferies maintains an Underperform rating, representing the most bearish stance among tracked coverage. Baader Europe/Alphavalue reiterated a Buy rating in June 2026, according to Wall Street analyst reports. Across these five most recent ratings, the distribution shows two Buy recommendations, two Hold ratings, and one Underperform, producing a moderately mixed consensus. Notably, no analyst has changed their directional view in recent actions, with all five reiterating prior ratings rather than upgrading or downgrading. This stability in analyst positioning suggests an established consensus framework around Roche, with limited catalysts prompting reassessment among the covering analyst community.
